SCHEMBL5730899

SCHEMBL5730899

CCS(=O)(=O)c1ccc(O)c(NC(=O)c2cc3cc(OC)ccc3[nH]2)c1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.57
KDM4E B2RXH2 11/20 0.57
MAPT P10636 7/20 0.57
NPSR1 Q6W5P4 1/20 0.54
RXFP1 Q9HBX9 1/20 0.54
BCAT1 P54687 1/20 0.53
NPC1 O15118 5/20 0.51
RAB9A P51151 5/20 0.51
L3MBTL1 Q9Y468 2/20 0.50
LMNA P02545 2/20 0.50
PRNP P04156 1/20 0.50
GAA P10253 1/20 0.50
PDGFRB P09619 1/20 0.50
PDGFRA P16234 1/20 0.50
HPGD P15428 1/20 0.50
HTT P42858 1/20 0.50
TP53 P04637 1/20 0.49
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5739687 0.86 TP53 (0.53) ALDH1A1KDM4EMAPTRXFP1NPC1
SCHEMBL5732186 0.85 MEN1 (0.53) ALDH1A1KDM4EMAPTNPSR1RXFP1
SCHEMBL5731508 0.85 NHERF1 (0.54) ALDH1A1KDM4EMAPTRXFP1BCAT1
SCHEMBL5750987 0.84 KDM4E (0.57) ALDH1A1KDM4EMAPTBCAT1NPC1
SCHEMBL6753662 0.78 ALDH1A1 (0.50) ALDH1A1KDM4EMAPTNPSR1RXFP1
SCHEMBL5740825 0.77 NPC1 (0.53) ALDH1A1KDM4EMAPTRXFP1BCAT1
SCHEMBL5731039 0.74 CYP1A2 (0.49) ALDH1A1KDM4EMAPTNPC1RAB9A
SCHEMBL7549923 0.74 ALDH1A1 (0.60) ALDH1A1KDM4EMAPTL3MBTL1LMNA
SCHEMBL13753883 0.74 KDM4E (0.77) ALDH1A1KDM4EMAPTNPC1RAB9A
SCHEMBL7551616 0.74 CYP1A2 (0.73) ALDH1A1KDM4EMAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1633709-A1 ANTI-DIABETIC AGENTS Pfizer Products Inc. (US) 2006-03-15 EP disclosed
WO-2004096768-A1 ANTI-DIABETIC AGENTS PFIZER PRODUCTS INC. (US) 2004-11-11 WO disclosed
US-20040220229-A1 insulin resistance; central nervous system disorders; vision defects; anticholesterol agents;antilipemic agents; antiischemic agents PFIZER INC 2004-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220229-A1 insulin resistance; central nervous system disorders; vision defects; anticholesterol agents;antilipemic agents; antiischemic agents IRS1, INSR, GPR119 ALDH1A1 1121/4885KDM4E 4572/4885MAPT 1216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.